Among eight genes including TP53 and KRAS being statistically significant (Figure 4A), PABPC1, CEP89, and RAD51B exclusively presented in the tumor evolution stage, which implied a possible association with heterogeneous drug responses (Table S6A, Supporting Information). The gene discussed is CEP89; the disease is neoplasm.